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Abstract 
Non-Hodgkin lymphoma (NHL) has been associated with immunological defects, chronic 
inflammatory and autoimmune conditions. Given the link between immune dysfunction and 
NHL, genetic variants in toll-like receptors (TLRs) have been regarded as potential predictive 
factors of susceptibility to NHL. Adequate antitumoral responses are known to depend on TLR9 
function, such that the use of its synthetic ligand is being targeted as a therapeutic strategy. We 
investigated the association between the functional rs5743836 polymorphism in the TLR9 
promoter and risk for NHL in three independent case-control association studies from Portugal 
(1160 controls, 797 patients), Italy (468 controls, 467 patients) and the U.S. (972 controls, 867 
patients). We found that the rs5743836 polymorphism was significantly over-transmitted in 
both Portuguese [odds ratio (OR), 1.85; P=7.3e-9] and Italian [OR, 1.71; P=5.2e-4] and not in an 
U.S. cohort of NHL patients. Our findings suggest the relevance of this functional TLR9 
polymorphism on NHL susceptibility in a population dependent manner.  
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Introduction 
Non-Hodgkin’s lymphoma (NHL) includes a heterogeneous group of malignant 
lymphoproliferative diseases whose incidence has substantially increased over the past decades 
in Western countries 1. Individuals with specific immune deficiencies associated with immune 
suppressive therapy after transplantation, human immunodeficiency virus (HIV) infection and 
congenital conditions are among those with higher incidence rates of lymphoid malignancies. 
Additionally, clinical and experimental data consistently associated several autoimmune and 
chronic inflammatory disorders with increased risk of NHL 2-3. 
Toll-like receptors (TLRs) are widely studied members of the pattern recognition 
receptor (PRR) family with a major role in activation and homeostasis of the immune system 
upon pathogen recognition 4. Among the TLRs that bind nucleic acids, TLR9 recognizes 
unmethylated CpG DNA motifs (present at a much higher frequency in the genomes of 
prokaryotes than of eukaryotes) as a “danger signal” that activates the innate immune system. In 
humans, this receptor is expressed in plasmacytoid dendritic cells (pDCs) and B lymphocytes, 
known to have a diverse TLR repertoire, where TLR9 predominates 5. A role for TLR9 on viral, 
fungal, mycobacterial and Helicobacter pylori infections has been described 6-10. TLR9 (and 
TLR7) has been also involved in the recognition of self-nucleic acids, which is believed to play an 
important role in the pathogenesis of autoimmune diseases, particularly in systemic lupus 
erythematosus 11 and psoriasis 12. 
In addition to self-recognition, inappropriate TLR9 activation leading to disease may also 
involve mechanisms of transcriptional deregulation of the TLR9 gene. Consistently, cells from 
different lymphoma types (mantle cell, B-cell small lymphocytic, follicular and diffuse large B-
cell) have been reported to overexpress TLR9 and to show an increased proliferation upon CpG 
stimulation, although with a heterogeneous pattern when comparing either different 
lymphomas or different patients 5, 13. More specifically, the highly prevalent rs5743836 
polymorphism in the TLR9 gene (1237T>C), has been demonstrated to predispose to Hodgkin 
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lymphoma as well as to several autoimmune and chronic inflammatory diseases, including 
asthma and Crohn’s disease 14-18. 
Given the substantial weight of evidence for immune dysfunction as the underlying basis 
of lymphomagenesis, a genetic variant unbalancing the regulation and expression of TLR9-
associated mechanisms may have a major impact upon host antitumoral responses and 
therefore, an important role in NHL pathogenesis. In the present study, we evaluated the 
association of the rs5743836 polymorphism in the TLR9 promoter with the risk of NHL. 
 
Results and Discussion 
Epidemiological and genetic studies have shown that inflammatory and infectious conditions, 
particularly bacterial and viral infections, are associated with increased NHL risk 3, 19-22, 
suggesting that chronic immune stimulation plays a role in NHL development 3, 21, 23-26. 
Given the role of TLR9 in bacterial and viral recognition, and the link of the TLR9 
rs5743836 polymorphism with Hodgkin lymphoma, we hypothesized that rs5743836 could also 
influence NHL risk. We therefore analyzed whether this polymorphism was associated with NHL 
susceptibility in a large-scale, case-control study. Genotype frequencies of Portuguese control 
individuals (n=1160) for rs5743836 were in Hardy-Weinberg equilibrium (P>0.05). A 
comparison of genotype distribution between the NHL patients (n=797) and controls revealed a 
positive association between the presence of rs5743836 and risk of NHL (Table 1), using the 
dominant (P=7e-9, odds ratio (OR)=1.85, 95% confidence interval (CI), [1.50-2.27]) or the 
additive (P=1e-7, OR=1.66) genetic models. To validate our findings, two independent Caucasian 
populations were used: an Italian cohort (467 NHL cases and 468 controls) and a U.S. population 
of European ancestry (972 NHL cases and 867 controls) 27. In both populations, rs5743836 
frequencies for controls were in Hardy-Weinberg equilibrium (P>0.05). Whereas the association 
was confirmed in the Italian cohort, with either the dominant (P=5.2e-4, OR=1.71, CI = [1.26-
2.33]) or the additive (P=1.1e-3, OR=1.49) genetic models, no association between NHL 
susceptibility and the presence of rs5743836 was found in the U.S. patients (Table 1). 
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There are several possible reasons for the discrepant results obtained for the association 
of rs5743836 with NHL. It is noteworthy that several other studies have found minor allele 
control frequencies of rs5743836 similar to those assessed in our European populations 8, 28-29. 
This suggests that, despite the fact that the populations enrolled in our study shared the same 
population bottleneck expanding out of Europe, the decreased minor allele frequency detected 
in the Portuguese and Italian cohorts likely reflects a greater genetic drift in Europe 30. On the 
other hand, familial aggregation and twin studies for lymphoproliferative disorders have ruled 
out the role of highly penetrant genes in affecting risk of the majority of NHL cases 31. It is 
therefore likely that the additive effects of genetic variants and interactions with environmental 
and infectious agents may play a significant role in the differential relevance of the rs5743836 
polymorphism in the risk for NHL. This hypothesis is in agreement with epidemiological and 
genetic studies showing that inflammatory and infectious conditions are associated with 
increased NHL risk, suggesting that chronic immune stimulation plays a role in NHL 
development 3, 20-22. 
The rs5743836 polymorphism in TLR9 has been consistently associated with increased 
transcriptional activity 9, 32-33. Therefore, it is possible to predict that the complex immunological 
response of various cell types to CpG, involving both direct and indirect effects of TLR9 is likely 
deregulated in individuals carrying the rs5743836 polymorphism. In fact, it has been shown that 
increased B-cell proliferation upon CpG stimulation is a common feature of different NHL 
subtypes, even though the proliferation pattern varies among NHL subtypes and individual 
patients 13. Signal transduction initiated by TLR9 activation results in nuclear translocation of 
NF-κB 34 that may enhance lymphocyte neoplastic transformation by promoting proliferation 
and survival of mutated cells 35. The neoplastic process leading to the development of NHL may 
be usurping impairments in TLR signaling pathways to advance cancer progression, which 
suggests that targeting these pathways may open novel therapeutic avenues. CpG molecules are 
now regarded as highly promising for cancer therapy, mostly due to their direct effect on TLR9 
activation on immune cell subpopulations that play an important role in anti-tumor immunity, 
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including B cells 36. However, therapeutic applications of these CpG should be individually 
tailored since individual genetic variations may affect the outcome of the TLR9 signaling 
pathway. 
In summary, our results suggest a potential role for the host genetic background in NHL 
susceptibility. However, deeper insights into the pathogenetic mechanisms underlying TLR9-
mediated mechanisms in NHL are needed. Ultimately, functional studies dissecting the role of 
the rs5743836 may allow the identification of potential therapeutic targets. 
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Table 1. Analysis of rs5743836 in non-Hodgkin lymphoma (NHL) patients and controls. 
 
 
 
 
 
 
a Portuguese and Italian patients had a mean age of 60.4±15.8 (51.7% males, 48.3% females) and 62.8±12.4 (58.9% males, 41.1% females), respectively. Controls 
were unrelated healthy blood donors frequency-matched to cases by gender and age. Patients and controls with history of transplantation, hematological malignancy 
or HIV infection were excluded from the study. U.S. patients derived from a study conducted in the San Francisco Bay Area (California, U.S.) that included incident 
cases diagnosed from 2001 through 2006. Details of the process and criteria for subject selection have been described elsewhere 27. All study participants provided 
written informed consent. 
b For the Portuguese and Italian studies, genotyping was performed using bi-directional PCR amplification of specific alleles (Bi-PASA) as described 37. For the U.S. 
study, genotyping was performed using a TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA) on a GeneAmp PCR System 9700 and a post-PCR plate 
read on the 7700 Sequence Detection System was used to determine genotype. Reactions were done with the following protocol: 95°C for 10 minutes, then 40 cycles 
of 95°C for 15 seconds, and 60°C for 1 minute. Probes and primer sets used were as follows: forward primer, GCCTTGGGATGTGCTGTTC; reverse primer, 
CAGAGACATAATGGAGGCAAAGGA; T probe, CCTGAAAACTCCC; and C probe, CTGGAAACTCCC. 
Population a Study Groups 
 
rs5743836 genotype b 
N (% frequency) 
 Statistical analysis c 
 TT TC CC TC + CC  P value* OR [95% CI]*  P value** OR** 
Portuguese 
Controls (1160)  934 (80.5) 217 (18.7) 9 (0.8) 226 (19.5)       
NHL (797)  551 (69.1) 244 (30.6) 2 (0.3) 246 (30.9)  7.3e-9* 1.85 [1.50-2.27]  1.1e-6** 1.66 
Italian 
Controls (468)  379 (81.0) 81 (17.3) 8 (1.7) 89 (19)       
NHL (467)  333 (71.3) 123 (26.3) 11 (2.4) 134 (28.7)  5.2e-4* 1.71 [1.26-2.33]  1.0e-3** 1.49 
U.S. 
Controls (972)  674 (69.3) 275 (28.3) 23 (2.4) 298 (30.7)       
NHL (867)  629 (72.5) 224 (25.8) 14 (1.6) 238 (27.5)  1.3e-1* 0.86 [0.70-1.0]  9.3e-2**  
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c Association tests were conducted using a dominant, recessive and an additive model (Cochran-Armitage trend test) tests. For the Portuguese and Italian studies, 
Fisher’s exact test and Pearson’s χ2 test were used to compare genotype frequencies between patients and controls. Unconditional logistic regression was used to 
compute odds ratios (ORs) and corresponding 95% confidence intervals (CI) adjusted for age and sex. For the U.S. study, association tests were conducted using the PLINK 
1.04 software. ORs and 95% CI were calculated by median-unbiased estimation using the mid-p method from the epitools R package 
(http://sites.google.com/site/medepi/epitools). P values were calculated regarding dominant* or the additive** genetic model. 
 
 
